BRIEF-FDA accepts Bristol-Myers Squibb's applications for Opdivo
July 24, 2017 at 16:34 PM EDT
* U.S. Food And Drug Administration accepts Bristol-Myers Squibb’s applications for Opdivo (nivolumab) four-week dosing schedule across all approved indications
